SAN DIEGO, Aug. 2, 2012 /PRNewswire/ -- Synteract, a leading full service contract research organization (CRO), is proud to announce Olivia Montano, senior director of clinical data management at Synteract, as one of the named recipients of the 2012 PharmaVOICE 100 award. The award given by PharmaVOICE magazine recognizes the top 100 thought leaders and innovators in the Life Sciences industry.
Montano, who was nominated by industry peers, is known for her contributions as a mentor and team leader, and for her significant impact on the high quality standards of both Synteract and the industry as a whole. Since joining Synteract in 1999 as one of its first 30 employees, she has been instrumental in the development and growth of its data management department, and most recently instituted an internal training program of 26 sessions for the SCDM clinical data manager exam. An active participant in biotechnology and pharmaceutical industry associations, Montano has been a subject matter expert for electronic data capture standards. She contributed to several chapters for the SCDM manual "Good Clinical Data Management Practices" and collaborated with CDISC as a subject matter expert on the CDASH guidelines and user guide.
"As senior director of clinical data management at Synteract Inc., Olivia Montano is having a significant impact on the high-quality standards of both her CRO and the industry as a whole," said Taren Grom, editor, PharmaVOICE. "She has built an incredible data management department at Synteract, and is drawing on her well-rounded background to set new and improved standards. Her dedication to the data field and to helping her colleagues and peers realize their goals are just a few of the reasons Ms. Montano is being recognized as a 2012 PharmaVOICE 100 honoree."
Honorees were identified in the July/August 2012 issue of PharmaVOICE magazine. The PharmaVOICE 100 are selected based on comprehensive submissions from industry professionals describing how nominees inspired or motivated them or affected positive changes as well as other factors, such as community and philanthropic activities. The annual award competition receives thousands of nominations each year from PhamaVOICE readers.
Wendel Barr, CEO of Synteract, says, "It is a pleasure to see Olivia recognized in this way. Olivia continues to maintain a big picture perspective as well as strong attention to detail in all she does. Olivia would tell you her biggest accomplishment is mentoring others to achieve their own potential to become great data managers. Her ongoing dedication to developing and supporting her team contributes to the efficiency and quality clients can expect from Synteract. She is most deserving of this industry recognition."
About PharmaVOICE (http://www.pharmavoice.com)
PharmaVOICE is written and designed to deliver the views, opinions, and insights of executives who are shaping the direction of the dynamic life-sciences industry. PharmaVOICE reaches more than 29,000 BPA qualified subscribers and more than 100,000 users with its digital edition, providing multiple perspectives on business challenges, trends, and topics. Its editorial content sparks dialog, initiates debate, and opens the lines of communication to facilitate and improve business-to-business relationships.
About Synteract (www.synteract.com)
Synteract is a full-service contract research organization with a successful 17-year track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. With its "Shared Work – Shared Vision" philosophy Synteract provides customized Phase I through IV services collaboratively and cost effectively to ensure on-time delivery of quality data so clients get to decision points faster. Headquartered in California, with offices in North Carolina and the Czech Republic, Synteract delivers trials internationally, offering expertise across multiple therapeutic areas including notable depth in oncology, CNS, cardiovascular, respiratory and ophthalmology.
|SOURCE Synteract, Inc.|
Copyright©2012 PR Newswire.
All rights reserved